EssilorLuxottica (OTCMKTS:ESLOY) Stock Price Up 7.8% – Still a Buy?

EssilorLuxottica Unsponsored ADR (OTCMKTS:ESLOY) traded up 7.8% during mid-day trading on Wednesday . The stock traded as high as $164.51 and last traded at $160.72. 45,800 shares traded hands during mid-day trading, a decline of 46% from the average session volume of 85,300 shares. The stock had previously closed at $149.14.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on ESLOY shares. Citigroup reaffirmed a “buy” rating on shares of EssilorLuxottica in a report on Thursday, December 11th. HSBC upgraded EssilorLuxottica from a “hold” rating to a “buy” rating in a research note on Wednesday, January 14th. The Goldman Sachs Group restated a “buy” rating on shares of EssilorLuxottica in a research report on Friday, December 5th. Zacks Research lowered shares of EssilorLuxottica from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 18th. Finally, Kepler Capital Markets upgraded shares of EssilorLuxottica from a “hold” rating to a “buy” rating in a research report on Thursday, January 15th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy”.

EssilorLuxottica Stock Performance

The business’s 50-day moving average is $159.97 and its 200 day moving average is $163.38. The company has a debt-to-equity ratio of 0.18, a current ratio of 0.97 and a quick ratio of 0.67.

EssilorLuxottica Company Profile

EssilorLuxottica SE is a global ophthalmic optics company formed through the 2018 merger of France-based Essilor and Italy-based Luxottica. Headquartered near Paris, the company combines lens manufacturing, frame design and production, brand management and retail operations to provide a vertically integrated offering across the vision care value chain. Its activities span product research and development, manufacturing, wholesale distribution and retailing of spectacles, sunglasses and ophthalmic lenses.

The company’s product portfolio includes prescription and non-prescription lenses, lens coatings and treatments, and an array of eyewear brands and frames.